Recent studies indicate that abnormalities of the interleukin-3 receptor (IL-3R) are frequently observed in acute myeloid leukemias (AMLs) and may contribute to the proliferative advantage of leukemic blasts. This review analyzes the evidences indicating that the IL-3R represents one of the target molecules involved in the stimulation of proliferation of AMLs, and the overexpression of the IL-3Ra chain may represent one of the mechanisms contributing to the development of a highly malignant leukemic phenotype. Furthermore, there is evidence that the IL-3Ra is a marker of leukemic stem cells, at variance with normal stem cells that are IL-3Ra À . Finally, the IL-3R may represent an important target for the development of new antileukemic drugs.
The current model on the pathogenesis of acute myeloid leukemias (AMLs) Several lines of experimental evidence suggest that multiple mechanisms are involved in the genesis of human tumors and, particularly, of AMLs. 1, 2 Among these different pathogenetic mechanisms, the occurrence of chromosomic translocations with consequent generation of fusion genes and corresponding fusion proteins play a major role in the genesis of these diseases. Stem cells are the main target for these key genetic events in acute leukemias. The major contribution of fusion proteins, such as PML/RARa, AML1/ETO, AML1/Evi1 or CBFb/SMMHC, consists in the capacity to block the differentiation process at a specific stage (reviewed in Tenen) . 3 Studies in transgenic mice harboring the fusion gene in their genome clearly indicate that the simple expression of this gene in hemopoietic cells greatly contributes to the differentiation block and, in some cases, also in part to the proliferative stimulation, but per se is not sufficient for the development of a leukemic condition. 4 This conclusion is directly supported by several experimental models, such as transgenic animals expressing the PML/RARa fusion gene: these animals, in spite a high expression of the transgene, need 1-2 years before the development of leukemia. This time is required for the acquisition in hemopoietic cells of additional mutations, mainly occurring at the level of genes involved in the control of cell proliferation, whose alterations are required for tumor development. Interestingly, similar observations have been also made in M2 leukemias associated with the t(8;21) translocation and the consequent formation of the AML1/ETO fusion protein.
Several lines of evidence have indicated that AML1/ETO is insufficient by itself to induce leukemia, but instead alters the self-renewal capacities of hematopoietic stem cells, resulting in the formation of a preleukemic population that lacks a great growth advantage. 5 For the development of an overt leukemic condition, AML1/ETO-induced effects must be associated with the effects of secondary mutations that cooperate with the primary mutation and ultimately result in a growth advantage and in a block of cell differentiation. 6, 7 In line with these findings, a high frequency of NRAS and c-kit mutations have been observed in AML patients with AML1/ETO þ leukemias. Therefore, it was proposed that fusion proteins encoding hybrid transcription factors require genetic complementation with mutant or activated kinases. Activated kinases could interfere with the cell cycle and complement the differentiation-blocking activity of chimeric transcription factors. This model is supported also by additional important observations: (a) fusion proteins, such as BCR/ABL or TEL/AML1 or AML1/ ETO, are found in normal subjects at a frequency about 100 times the corresponding leukemia rates, 8, 9 thus indicating that their presence in few hemopoietic cells is per se not sufficient for the development of a leukemic condition; (b) the analysis of the clonal relationship of concordant leukemia in identical mozygotic twins strongly argues in favor of a parental in utero origin of pediatric leukemias. 10 In the recent years several genes have been identified, mutated or abnormally expressed in AML, that confer a proliferative survival advantage to leukemic blasts. These genes are characterized by their involvement in the control of cell proliferation. Thus, the hemopoietic receptor tyrosine kinase Flt3 is constitutively activated in 30-35% of cases of AML, as a consequence of internal tandem-repeat mutations in the juxtamembrane domain, or activating loop mutations (reviewed in Gilliland and Griffin). 11 Similarly, Flt3 is frequently overexpressed in secondary, therapy-related AMLs 12 and in lymphoblastic leukemia with MLL rearrangements 13 and with hyperdiplody.
14 Finally 5-10% of patients with myelodysplasia have mutations of the Flt3 gene. The occurrence of a significant association between the presence of Flt3 mutations in AML and the number of blast cells strongly indicates that the mutated receptor induces a proliferative biologic effect in leukemic blasts. Activating loop mutations have been identified in the hematopoietic receptor tyrosine kinase c-kit in 5% of AML cases. 15 Furthermore, activating loop mutations in RAS family members, mainly NRAS and KRAS, have been identified in 15-25% of cases. 16 It was estimated that mutations of some components of the receptor tyrosine kinase pathway (including Flt3, c-kit, VEGFRs, c-fms and RAS) occur in 450% of AML patients.
Recent studies indicate that abnormalities of the interleukin-3 receptor (IL-3R) are frequently observed in AMLs and may contribute to the proliferative advantage of leukemic blasts. This review will analyze the evidences indicating that the IL-3R may represent one of the target molecules involved in the stimulation of proliferation in AMLs and particularly, that its overexpression may represent one of the mechanisms involved in the pathogenesis of a highly malignant leukemic phenotype. This review will not cover the basic physiology of the IL-3R, as well as the signal transduction pathways induced by the activation of this receptor since this topic was covered by an excellent review, recently published on this journal. 18 
Basic background
Normal hematopoiesis is a multistep process in which lineage development occurs as a consequence of the initial stochastic differentiation of pluripotent stem cells with the generation of multipotent hemopoietic progenitors and the subsequent differentiation along the different hemopoietic lineages of these cells under the ordered effects of a number of growth factors. These growth factors may be classified according to the level of their biological action as early-acting hemopoietic growth factors (HGFs), multilineage HGFs and late-acting HGFs. The prototype of multilineage HGF is represented by IL-3.
The main biologic activity of IL-3 is exerted at the level of the progenitor compartment, where this cytokine stimulates the survival and proliferation of multipotent cells; particularly, IL-3 stimulates the development of multilineage colonies from normal bone marrow, but displayes also effects at the level of the compartment of hemopoietic precursors, restricted to the granulocytic and monocytic lineages. 19, 20 IL-3, as well as GM-CSF, exerts its biologic activity through the interaction with cell surface receptors that consist of two subunits, the a subunit specific to each and the b common chain (bc). The a chain (IL-3Ra, GM-CSFRa) binds IL-3 and GM-CSF, respectively, with high specificity, but with low affinity. 19, 20 The interaction of an a chain with a b chain leads to the formation of a high-affinity receptor complex able to bind the respective ligand in the range of its physiologic concentrations and to transduce proliferative, antiapoptotic and differentiative signals. 19, 20 The bc expressed alone, in the absence of a specific a chain, confers little binding affinity for either IL-3 or GM-CSF. 21 Although the bc of the IL-3/IL-5/GM-CSF receptors initiates signal transduction events specific for this receptor family, it apparently does not distinguish between IL-3, IL-5 and GM-CSF. It is obvious that the cytokine-specific a-chains are candidates to confer specificity in signaling between IL-3, GM-CSF and IL-5. The IL-3Ra and GM-CSFRa intracellular domains are relatively short (about 30 amino acids), but seem to play a critical role in signaling transduction, in that their deletion leads to the abrogation of receptor signaling. The intracytoplasmic regions of all three IL-3Ra, GM-CSFRa and IL-5Ra contain a highly conserved membrane-proximal proline-rich region, involved in receptor signaling. Near this region, a tripeptide whose sequence is different in IL-3Ra compared to GM-CSFRa was recently identified. This tripeptide seems to confer to IL-3R a differential biologic activity as compared to GM-CSFR: in fact, in a multipotential murine hemopoietic precursor cell line (FDCP-mix cells), the transfection of IL-3R resulted in a stimulation of cell proliferation, while the transduction of GM-CSFR resulted in a stimulation of cell differentiation; 22 the transduction of a mutatnt GM-CSF receptor containing a tripeptide sequence mutated from its own sequence to the IL-3R sequence, induced a shift of the biologic activity of GM-CSF from induction of differentiation to induction of proliferation; 23 similarly, the mutated IL-3R with the tripeptide sequence of the GM-CSFR acquired biologic activity on cell differentiation and losted its activity on cell proliferation of FDPC-mix cells. 23 According to these observations, it was suggested that IL-3 exerts its biologic activities mostly at the level of the control of proliferation of hemopoietic progenitors, while the predominant effect of GM-CSF is on the differentiation of these cells.
The analysis of the signal transduction pathways triggered by IL-3R activation is out the scope of the present review, and the reader is referred to an excellent review recently published on this journal. 18 Here, only a brief summary of this process is briefly oultined. After ligand binding, the IL-3R/GM-CSFR bc becomes phosphorylated, and through the recruitment of adaptor proteins such as Shc, Grb2, and Sos activates the Ras signaling pathway. The activated Ras pathway in turn stimulates Raf followed by the downstream induction of the MAPK pathway related to ERK1 and ERK2, linked to increased expression of the transcription factors c-fos and c-jun. The activation of the MAPK pathway is not restricted only to ERK1 and ERK2, but involves also p38, and JNK/SAPK. Another very important transduction pathway induced during the activation of the IL-3R is represented by the phosphatidylinositol 3-kinase (PI-3K)/AKT pathway: the p85 subunit of PI3 K associates with the bc of the activated IL-3R at the level of phosphorylated Ser-585, 24 recruits PKB/AKT by phosphorylation of its serine residues and transmits several survival signals. Ultimately, these various transcription pathways influence in a specific way gene transcription activating or repressing a set of transcription factors, cause cell to progress through cell cycle check points via the activation of specific protein kinases and inhibit apoptosis basically through the phosphorylation of specific proteins involved in the apoptotic cascade.
As above mentioned, one of the main effects exerted by both IL-3R and GM-CSFR consists in inducing an inhibitory effect on cell apoptosis. In this process, a major role is played by the activation of the p38 MAP kinase and PI3K/AKT pathways. A key target of both these transduction pathways activated by IL-3 is represented by the Mcl-1 gene, a member of the Bcl-2 family of proteins. Mcl-1 is an immediate early gene activated by the IL-3 signaling pathways and representes one major component of the viability response elicited by this cytokine. 25 One additional important target for the PI3K/AKT pathway is represented by NFkB: this transcription factor is held in an inactive, latent state in the cytoplasm by the inhibitor protein IkB; AKT phosphorylates IkB kinase that in turn phosphorylates IkB with its consequent degradation by the proteasome, allowing NFkB to translocate to the nucleus and regulate the expression of a broad of genes such as bcl-2, bcl-X L and A1, all involved in cell survival. 26 This pathway is activated by IL-3 via phosposerine-585 bc phosphorylation. 26 According to all these observations it was proposed that the antiapoptotic activity of IL-3 could be related to the induction of the Bcl-2 family genes, bcl-2, bcl-X L , A1 and mcl-1. 27 The screening by microarray gene expression profiling of genes downmodulated by IL-3 deprivation in an IL-3-dependent cell line following IL-3 starvation provided evidence that pim-2 is the gene most modulated by IL-3. 28 Pim-2, a serine threonine kinase, emerged from these studies as a candidate for a key mediator of survival signaling by IL-3: in fact, pim-2 knockout or overexpression of a pim-2 dominant-negative mutant, prevented effctive survival signaling by IL-3. 28 Pim-2 seems to act as an activator of several antiapoptotic pathways. 29 Finally, SHP-2, a tyrosine phosphatase, highly expressed in hematopoietic cells seems to play multiple and important roles in IL-3 signal transduction. In fact, the IL-3-induced proliferative response is markedly dimished in SHP-2 (À/À) cells. 30 
IL-3R in acute leukemia U Testa et al
Aberrant activation of both the Ras/MEK/ERK and of the PI3K/ AKT pathways is commonly observed in AMLs: the targeting of some key molecules of these pathways may represent an important tool for the development of new therapeutical approaches. [30] [31] [32] [33] [34] Oncogenic role of IL-3/IL-3R in experimental models
The role of IL-3Ra and b chain genes in oncogenesis has been explored in several animal models. A first series of experiments showed that certain mutations of IL-3Rb may determine growth factor independency and tumorigenicity. A mutant form of IL3Rb chain was isolated from growth factor-independent cells, which arose spontaneously after infection of a murine factordependent hematopoietic cell line (FDC-P1) with a retroviral IL3Rb expression construct. 35 Analysis of this mutant shows a small (37 amino acid) duplication of extracellular sequence that includes two conserved sequence motifs: this mutation is sufficient to confer growth factor-independent growth of these cells and induces a tumorigenic phenotype. 35 Furthermore, the IL-3Rb chains are truncated in spontaneous mutants of a murine promyelocytic cell line, determining growth factor independency, due to constitutive IL-3R activation. 36 The expression of this truncated IL-3Rb subunit in factor-dependent myeloid cells (FDC-P1) did not immediately render the cells autonomous, but increased the spontaneous frequency to factor-independent growth. 36 A second mutation of the IL-3Rb chain, V449E, results in substitution of a valine residue in the transmembrane domain with glutammic acid. 37 Interestingly, when expressed in the IL-3-dependent murine pro-B-cell line, BAF-B03, this mutant, but not the extracellular mutant, could confer growth factor independency. 37 The finding implies that the extracellular and transmembrane mutants signal via different mechanisms, and that the extracellular mutant may require other signaling molecules to deliver a mitogenic signal. In line with this hypothesis, studies on primary hemopoietic progenitors showed that retroviral expression of the extracellular mutant confers factor-independent proliferation on cells of the neutrophilic and monocytic lineages only, while expression of the transmmebrane mutant exerts this effect on cell myeloid lineages, as well as in erythroid cells. 38 Mutations of the IL-3Ra gene have been described in A/J mouse and related mice strains. Particularly, bone marrow cells of A/J mice are nonresponsive to IL-3 and this property depends on an aberrant splicing of IL-3Ra mRNA and impaired expression of the IL-3Ra chain, in that the mutant protein is localized inside the cells and not on the cell surface. 39 The A/J mice have a high incidence of lung adenomas and leukemias. 40 In addition to these models, where the mutation of either the IL-3Ra or IL-3Rb chains may contribute to the development of a leukemic condition, other studies have suggested a possible oncogenetic role related to the level of expression of these receptors. Therefore, in v-abl derivatives of the IL-3-dependent FL5.12 cell line, the induction of an autocrine mechanism of IL-3 production was associated with an absent downmodulation of IL-3Rb chain expression. 41 In parental cells, as well as in other normal cells, IL-3Rb is downmodulated following exposure of the cells to IL-3. In another study the effect of IL-3Ra and b overexpression in FDC-P1 cells was directly evaluated. The overexpression of both these receptor chains elicited two major effects: (a) it increased the sensitivity to IL-3 (ie, the cells proliferated in the presence of suboptimal IL-3 concentrations); (b) it favored the development of IL-3-independent clones. 42 Other studies were focused to evaluate the effect of IL-3Rb chain deficiency both in mice and in humans. Mice lacking IL3Rb chain show a pulmonary alveolar proteinosis-like disease. 43 Interestingly, these animals showed normal hematologic parameters, with the exception of a reduced eosinophil number. 43 A similar situation was observed in children with human pulmonary alveolar proteinosis, where in a high percentage of cases a deficit of the IL-3Rb chain was observed. 44 This syndrome is also observed in an adult form: in this case it is due to the development of an anti-GM-CSF autoimmunity. 45 Interestingly, in a part of the pediatric patients, the development of pulmonary proteinosis is associated to AML. 46 In these patients, the expression of bc chain was markedly reduced, while IL-3Ra expression was normal. 47 After antileukemic treatment, the pulmonary symptoms resolved and the bc expression was normal. 47 
IL-3R expression in leukemias
Initial studies based on the analysis of the biological responses elicited in vitro by IL-3 addition and on the study of the binding of -IL-3 to membrane receptors showed that most human AML blasts proliferate in response to IL-3 and express IL-3Rs. [47] [48] [49] [50] Particularly, in more than 85% of AML cases, IL-3 elicited a clear stimulation of thymidine incorporation and, as a single stimulatory agent, was significantly more active than other hemopoietic growth factors. 47, 48 Similarly, the analysis of IL-3 binding to AML blasts showed that 480% of AMLs exhibit highaffinity IL-3 receptors. 49, 50 More recently, the availability of antibodies specific for the a and b chain of the IL-3R allowed the evaluation in detail of the expression of these two receptors chains in leukemias. Particularly, antibodies interacting with the N-terminal of the IL-3Ra chain and blocking the binding of IL-3 to its receptor, as well as antibodies interacting with other regions of the molecule that fail to inhibit IL-3 binding or function, have been developed. 51 In parallel, antibodies specifically interacting with the common IL-3R/GM-CSFR/IL-5R b-chain have been developed, thus allowing to explore the expression of both IL-3R chains. The study of normal IL-3Ra during normal hemopoietic differentiation provided evidence that this receptor chain was clearly expressed in CD34 þ HPCs and its expression was maintained during all stages of granulocytic and monocytic differentiation, while it was lost after the initial stages of erythroid and megakaryocytic differentiation. 52 The IL-3R/GM-CSFR/IL-5R bc was expressed at low levels in CD34 þ cells and its expression increased during initial stages of granulocytic and monocytic differentiation and therefore maintained up to the late stages of maturation, while it was transiently expressed in the erythroid and megakaryocytic differentiation only during the early stages of differentiation and then disappeared. 53 The screening of IL-3Ra expression in hemolymphopoietic malignancies provided evidence that this receptor chain is expressed in the large majority of B-ALL and AML, is usually not expressed in T-ALL as well as in the majority of lymphomas, is highly expressed in hairy cell leukemia. 54 These findings have been confirmed on a large series of acute leukemias, clearly indicating that an elevated expression of IL-3Ra is mainly observed in AML and B-ALL. 13 We observed also that IL-3Ra chain is overexpressed (ie, it is expressed at levels significantly higher than those observed in normal CD34 þ cells, the normal cells expressing the highest levels of IL-3Ra chain) (Figure 1a) , in 40% of patients with B-ALL and in 45% of patients with AML. 17 IL-3R-overexpressing AMLs have been observed along all the IL-3R in acute leukemia U Testa et al FAB AML subtypes. However, the analysis of the membrane immunophenotype of AMLs expressing high levels of IL-3Ra chain showed several interesting findings: usually, these leukemias show high expression of CD34 (Figure 1a ), CD33 and CD13 antigens, constantly associated with a low CD15 and CD11b expression; interestingly, the large majority of ILRa þ þ þ AMLs dislpay a clearly detectable expression of both c-kit and flt3, with a high proportion of leukemic blasts being ckit þ and flt3 þ . The biological consequences of this overexpression pattern were investigated in AMLs, showing that: (i) in all patients, the blasts expressing elevated IL-3Ra levels exhibit higher cycling activity (Figure 1b) and increased resistance to apoptosis triggered by growth factor deprivation; (ii) spontaneous Stat5 phosphorylation was frequently observed only in AML patients exhibiting high levels of IL-3Ra expression; (iii) following IL-3 treatment, Stat5 was activated at significantly higher levels in blasts with elevated IL-3Ra expression than in blasts with IL-3Ra levels comprised within the normal range. 17 Given the peculiar properties of leukemic blasts expressing high levels of IL-3Ra, we then explored the possible association between elevated IL-3Ra expression and the response to therapy. In this context, we observed that: (i) there is a good correlation between IL-3Ra levels and the number of leukemia blasts at diagnosis, suggesting a role for IL-3Ra in leukemic blast proliferation/survival; (ii) patients with elevated levels of IL-3Ra on their leukemic blasts exhibited a reduced number of complete remissions, higher relapse rate and a lower survival than patients with normal/low IL-3Ra levels. 17 According to the ensemble of these findings it was suggested that in AML deregulated expression of IL-3Ra may contribute to the proliferative advantage of the leukemic blasts and, hence, to a poor prognosis. 17 In line with these findings, studies on cell lines have clearly shown that IL-3R overexpression induces oncogenic effects: particularly, IL-3Ra overexpression did not completely relieve factor dependency, but allowed the cells to proliferate in the presence of suboptimal concentrations of IL-3. 41 On the basis of 
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U Testa et al these observations, it was concluded that a deregulation of IL3Ra expression may provide a proliferative advantage to hemopoietic cells growing under conditions in which the cytokine is limiting and allows the development of a leukemia. 41 In addition to these findings, another study extended the analysis of IL-3Ra to subpopulations of AML blasts and, particularly, to leukemic stem cells (ie, the subpopulation of leukemic blasts, corresponding to cells that maintain the leukemic process and that seemingly represent the main target of the initial leukemic transformation). 55 The analysis of an AML subpopulation enriched in leukemic stem cells (ie, 34 þ /38 À ) showed that these cells express high levels of IL-3Ra, while in the normal counterpart (ie, in 34 þ /38 À cells isolated from normal controls) low level of IL-3Ra have been observed, thus suggesting that IL-3Ra represents an unique marker for AML stem cells. 55 According to these findings, it was shown that the isolation of 34 þ /38 À /IL-3Ra þ þ cells represent an efficient system for the purification of leukemic stem cells in AML patients. 56 It is clear that the mechanism through which an overexpressed IL-3Ra may induce a growth advantage in AML blasts is related to the induction of a constitutive Stat5 activity. The constitutive Stat5 activation is a pathway involved in many hematologic malignancies. Translocations resulting in TEL-JAK2 57 or TET-PDGFbetaR 58 constructs lead to the constitutive Stat5 activation and to IL-3 independency. Similarly, in chronic myeloid leukemia (CML), Stat5 is constitutively activated through a mechanism involving the interaction between Bcr/ Abl and the hemopoietic cell kinase (HCK). 59 The inhibition of the Bcr/Abl kinase activity by specific inhibitors blocks the constitutive Stat5 activation and growth of CML cells. 60 Interestingly, recent studies provided evidence that the Flt3 mutations are also able to activate the Stat5 pathway. The Flt3 receptor, a tyrosine kinase, is constitutively activated either by internal tandem duplication or by point mutations in 430% of AML patients. 11 It was clearly shown in large series of patients that the presence of a mutated Flt3 was associated to a poor prognosis and to the development of a leukemia with an aggressive phenotype (high blast cell counts at diagnosis), findings similar to those observed in the group of AML patients overexpressing the IL-3Ra chain (reviewed in Gilliland and Griffin 11 and Stirewalt and Radich 61 ). Recent studies clearly indicate that the mechanism through which the mutated Flt3 confer to leukemic blasts a growth advantage is mainly related to the capacity to constitutively activate the Stat5 transduction pathway. In fact, it was shown that the majority of AML patients with Flt3 mutations and particularly with ITD mutations exhibit a constitutive Stat5 activation. 62 Similarly, Sta5 is activated in lymphoid leukemic cells with D835/I836 mutatation. 63 Interestingly, the wt Flt3 receptor does not signal through the Stat5 pathway, but via AKT and MAPK pathways. 64, 65 Importantly, the incubation of these leukemic blasts with inhibitors of the Flt3 kinase activity elicited an inhibition of Stat5 activity and of the expression of Bcl-X L (a target gene of Stat5), thus indicating that the constitutive Flt3 receptor signaling is responsible for Stat5 activation. 65, 66 In line with these observations, microarray analysis showed that the target genes of mutationally activated Flt3 resembled more closely those of the IL-3R than those of ligand-activated wt Flt3. 67 The role of Flt3 mutations in the genesis of highly, alignant forms of leukemia renders FLT3 an obvious target of therapy. Several small-molecule FlT3 inhibitors are under development and are under evaluation in phase I/II studies. 68 Since a constitutive Stat activation was also observed in AML patients exhibiting IL-3Ra overexpression, experiments are in progress to evaluate whether there is an overlapping between Flt3 mutations and IL-3Ra overexpression.
From a more general point of view it of interest to note that Flt3 mutations are considered in recent views on the pathogenesis of acute leukemias as the prototype of class I mutations, that is, of those mutations that induce a proliferative advantage to leukemic cells. 3 In addition to the Flt3 mutations, also the IL-3Ra overexpression should be considered, although it is not a mutation, another type of abnormality of leukemic cells contributing, like Flt3 mutations, to confer to leukemic blasts a proliferative advantage. This conclusion is directly supported by the analysis of animal models of development of acute leukemia, where IL-3R stimulation, as well as Flt3 mutations, cooperated with chimeric transcription factors in inducing a leukemic condition. 69 Within the family of receptors that use the common bc, the overexpression of IL-3Ra in AMLs is specific in that both the GM-CSFRa and the IL-5Ra chains are not overexpressed. Particularly, the GM-CSFRa is preferentially expressed in myeloid compared to lymphoid leukemias and its level of expression is in the majority of cases comparable to those observed in normal hemopoietic cells at a comparable degree of differentiation. 17 In addition to the IL-3Ra, few studies have explored the expression of bc in acute leukemias.The expression of bc was preferentially observed in AMLs, at levels of expression comparable to those observed in the normal counterpart. Interestingly, in many leukemic patients, a markedly increased level of a truncated form (b IT ) of the bc was observed. 70 This b IT has a tail of 46 amino acids, instead of 432 for bc, with 23 amino acids in common with bc and a new sequence of 23 amino acids. 70 The proportion of b IT increased to 90% of total bc content in blast cells of a significant proportion of AML patients. 62 The b IT was unable to transduce a proliferative signal and it was proposed that it could act as a dominant negative interfering with the signal-transducing properties of the bc, and could play a role in the differentiation blockade of leukemic cells. 70 In addition to abnormalities of IL-3R expression, in some leukemias, an autocrine production of IL-3 by leukemic cells was found. This condition was studied in detail in CML. A first series of studies showed that the expression of BCR/ABL confers autonomous growth properties on a variety of cell lines dependent on IL-3 for their growth. 71 Acquisition of growth factor independence was associated with the induction of IL-3 production. 71 This mechanism of autocrine IL-3 production was shown to be activated in primitive hemopoietic progenitor (CD34 þ ) cells of CML patients: this IL-3 production activates an autocrine stmulatory loop that leads to constitutive Stat5 activation. 71 Interestingly, this autocrine IL-3 production mechanism declines when leukemic cells differentiate. There is evidence that IL-3 production by CML cells is directly and rapidly induced by BCR/ABL in early hemopoietic progenitor cells. 72 Importantly, the shift of early CML progenitors from a growth factor-dependent growth to autonomous growth is associated with acquisition to synthesize and release IL-3. 73 Similarly, there is evidence that a significant proportion of AMLs secrete IL-3 or GM-CSF. 74, 75 In a study carried out on 53 AML patients, clearly detectable levels of IL-3 have been detected in about 80% of the leukemic blast cell culture supernatants. 76 The highest IL-3 secreting capacity was observed in M1/M2/M3 AMLs. 76 It is of interest to note that in this study was reported the capacity of IL-3 to stimulate the production of secondary cytokines, such as IL-6, TNF-a and IL-1b by leukemic cells. 76 Interestingly, IL-3 or GM-CSF IL-3R in acute leukemia U Testa et al production by leukemic blasts was observed also at the level of early progenitor leukemic cells, that is, at the level of the leukemic blasts that initiate and maintain the leukemic process. 77 It is of interest to note that an autocrine Flt3 activating loop was recently described in AML cells. 78 In fact, it was observed that the majority of AMLs not only express the Flt3 receptor but possess also the capacity to synthesize and secrete its ligand. 78 This autocrine Flt3 ligand production leads to an autocrine stimulatory loop with consequent constitutive Flt3 autophosphorylation and activation. 78 Interestingly, this phenomenon occurs both in patients with Flt3 mutataions and with wild-type Flt3. The autocrine Flt3 ligand production was also found at the level of very early leukemic progenitors, thus suggesting that the Flt3 activation may play a role in the stimulation of early leukemic progenitors. 77 
Development of therapeutical approaches tailored to the IL-3R
Taking advantage on the development of the studies on IL-3 and IL-3R expression in AMLs, several investigators have explored the efficacy of drugs based on a diphteria toxin (DT) human IL-3 fusion protein. The basic idea is that the fusion protein interacts with the leukemic blasts expressing high levels of IL-3R, is internalized and exerts its highly cytotoxic effects. These studies have been initially carried out in murine models showing that DT-murine IL-3 fusion protein is toxic for murine IL-3-bearing leukemic cell lines, but spares the majority of normal mouse bone marrow-repopulating stem cells. 79, 80 Two subsequent studies have evaluated the effect of a DT human IL-3 fusion protein on AML blasts. In an initial study, it provided preliminary evidence that a DT human IL-3 fusion protein was more cytotoxic for AML blasts than for normal bone marrow hemopoietic progenitors. 81 In a second study, the issue was studied in more detail showing that: (i) a high percentage of AML progenitors or AML LTC-IC ('long-term culture-initiating cells') were killed by the IL-3 fusion protein, with most of the surviving progenitors being cytogenetically normal; (ii) a significant proportion of normal hemopoietic progenitors was killed by, while LTC-ICs were not significantly killed by DT/IL-3; (iii) a significant proportion of leukemic, but not of normal repopulating stem cells, as evaluated by the NOD/SCID assay, was killed by the DT/IL-3; (iv) the in vivo administration of DT/ IL-3 markedly reduces the engraftment of AML cells in NOD/ SCID mice. 82 On the basis of these observations, the same investigators have evaluated the antileukemic activity of DThuman IL-3 in the treatment of immunocompromised mice engrafted with human IL-3R-positive AML blasts. The results of these studies showed a substantial killing of malignant progenitors in vivo by DT-IL3, with a potency inferior to that of a standard antileukemic cytotoxic drug, such as cytarabine, but with a potency comparable to that displayed by other agents for target-specific therapy (such as DT-GM-CSF or anti-CD33-calicheamicin). 83 These observations warrant the further preclinical development of DT-IL-3. This drug could be useful in the treatment of patients refractory to standard chemotherapy or in association with chemotherapy. Furthermore, DT-IL3 could have a toxicity profile more favorable than DT-GM-CSF. In fact, the fusion protein between GM-CSF and diphteria toxin has been developed as a clinical grade reagent and was used for the treatment of AML patients resistant to standard chemotherapy: on 31 treated patients, three remissions have been observed. 84 However, the DT-GM-CSF produced dose-limiting toxicity due to liver injury related to the binding of GM-CSF receptors present on the surface of liver macrophages. 84 Since IL-3Rs were not present on liver macrophages, it is expected that DT-IL3 may have a better toxicity profile and a wider therapeutic index than DT-GM-CSF.
